|
Drug
Category
|
Description
|
Drug
Name and Drug Sponsor
|
FDA
Status
|
| Interferons
|
Fusion protein Interferon alfa-albumin
|
Albuferon
(Human Genome Sciences)
|
Phase II
|
|
Purified multi-subtype human IFN alfa
|
Multiferon
(Viragen)
|
Phase II
|
|
Pegylated alfacon-1
|
Peg-alfacon
(InterMune)
|
Phase 1
|
|
Interferon omega
|
Omega interferon
(Biomedicines)
|
Phase I
|
|
Medusa interferon
|
Medusa Interferon
(Flamel Technologies)
|
Phase II
|
|
Interferon beta-1a
|
Rebif
(Ares Serono)
|
Phase III
|
|
Oral interferon alfa
|
Oral interferon alfa
(Amarillo Biosciences)
|
Phase I
|
|
Ribavirin Alternatives
|
Amidine prodrug of ribavirin
(nucleoside analogue)
|
Viramidine
(Valeant Pharmaceuticals)
|
Phase 3
|
|
IMPDH inhibitors
|
Merimepodib
[VX-497]
(Vertex
Pharmaceuticals)
|
Phase 2
|
|
Mycophenolic acid
|
Mycophenolic
acid
(Roche
Pharmaceuticals)
|
Phase 1
|
|
Antiviral
|
Amantadine
(Endo Labs, etc)
|
Phase 3
|
|
Immunomodulators
|
Augmented T-cell function
|
Thymosin
alfa-1 [Zadaxin]
(Sci-Clone)
|
Phase 3
|
|
Enhanced IFN activation of T and natural killer cells
|
Histamine
dihydrochloride (Ceplene)
(Maxim
Pharmaceuticals)
|
Phase 2
|
|
Therapeutic vaccine
(viral E1 protein of HCV)
|
E1
vaccine
(Innogenetics)
|
Phase 2
|
|
Therapeutic vaccine
|
IC-41
(Intercell)
|
Phase 2
|
|
Vaccine
|
HCV-MF59
(Chiron)
|
Phase 1
|
|
Inhibitors of Viral Enzymes
|
synthetic
oligonucleotide and selective TLR9 agonist
|
Actilon
(Coley)
|
Phase 1/2
|
|
NS3 serine protease inhibitor
|
BILN-2061
(Boehringer
Ingelheim)
|
Phase 2
(on hold)
|
|
Serine protease inhibitor
|
Sch-6
(Schering-Plough)
|
Phase 1
|
|
NS3-4A protease inhibitor
|
VX-950
(Vertex Pharmaceuticals)
|
Phase 2
|
|
RdRp inhibitor
|
Valopicitabine
[NM-283]
(Idenix
Pharmaceuticals)
|
Phase 1/2
|
|
Polymerase inhibitor
|
JDK-003
(Akros
Pharmaceuticals)
|
Phase 1
|
|
Polymerase inhibitor
|
HCV-896
(ViriPharma)
|
Phase 1
|
|
Antifibrotics
|
Antisense oligonucleotide
|
ISIS-14803
(Isis Pharmaceuticals)
|
Phase 2
|
|
Anti-tumor
necrosis factor α (FDA-approved for treatment of arthritis)
|
Enbrel
(Wyeth-Ayerst)
|
Phase 1
|
|
Oral
phospholipid antifibrotics
|
IP-501
(Indevus Pharmaceuticals)
|
Phase 3
|
|
Others
|
Caspase
inhibitors
|
ID-6556
(Idun Pharmaceuticals)
|
Phase 2
|
|
Anti-CD20
mononclonal antibody
|
Rituximab
(Genentech)
|
Phase 1/2
|
|
Monoclonal
antibody
|
XLT-6865
(XTL)
|
Phase 1/2
|
|
Prodrug
of isatoribine
|
ANA-971
(Anadys)
|
Phase 1
|
|
Prodrug
of isatoribine
|
ANA-245
(Anadys)
|
Phase 1/2
|
|
Anti-phospholipid
|
Tarvacin
(Peregrine)
|
Phase 1
|
